Mitul Patel, DO
Cardiovascular Disease · Browns Mills, NJNPI 1295140382
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.1%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 38.5% of the total. Reporting peaked in 2020 at $3,958 and has fallen 82.4% since, to $697 in 2025.
Across 64 payments — averaging $127.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Shockwave Medical, Inc$2K
- Cvrx, Inc.$671
- Abbott$355
- Abiomed$262
- plus $446 from 8 others
Across 1 payment — averaging $12,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$12K
What the payments were for
- Grants$3,70546%
- Travel & lodging$6718%
- Food & beverage$3,75446%
- Gifts$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $3,137 |
| Boston Scientific | 11 | $1,749 |
| Shockwave Medical, Inc | 28 | $1,517 |
| Cvrx, Inc. | 2 | $671 |
| Abbott | 3 | $355 |
| Abiomed | 2 | $262 |
| Cardiovascular Systems Inc. | 1 | $145 |
| Stryker | 1 | $134 |
| Johnson & Johnson | 4 | $65 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Novartis | 1 | $22 |
| Chiesi USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - STRUCTURAL HEART$1,105
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,088
- Barostim Neo System$671
- CoreValve Evolut$465
- Diamondback Peripheral$155
- Coronary Orbital Atherectomy System$145
- AVVIGO Guidance System$140
- CLOTTRIEVER BOLD CATHETER$134
- Perclose ProGlide suture mediated closure system$129
- Impella$129
- GENERAL - THERAPIES$107
How this compares
$8,139 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $74,860 |
| XareltoRivaroxaban | 17 | $19,671 |
| Atorvastatin Calcium | 69 | $1,567 |
| Metoprolol Succinate | 82 | $1,323 |
| Valsartan | 25 | $925 |
| Rosuvastatin Calcium | 87 | $765 |
| ClopidogrelClopidogrel Bisulfate | 25 | $583 |
| Diltiazem Hcl | 14 | $474 |
| Amiodarone Hcl | 13 | $395 |
| Amlodipine Besylate | 45 | $386 |
| Lisinopril | 25 | $312 |
| Pantoprazole Sodium | 13 | $285 |
| Furosemide | 46 | $270 |
| Losartan Potassium | 26 | $208 |
| Ezetimibe | 13 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $65 | $19,67117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Browns Mills
- Richard KovachBrowns Mills$300K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.